Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014.
dc.contributor.author | Solomon, B | |
dc.contributor.author | Cappuzzo, F | |
dc.contributor.author | Felip, E | |
dc.contributor.author | Blackhall, Fiona H | |
dc.contributor.author | Costa, D | |
dc.contributor.author | Kim, D | |
dc.contributor.author | Nakagawa, K | |
dc.contributor.author | Wu, Y | |
dc.contributor.author | Mekhail, T | |
dc.contributor.author | Paolini, J | |
dc.contributor.author | Tursi, J | |
dc.contributor.author | Usari, T | |
dc.contributor.author | Wilner, K | |
dc.contributor.author | Selaru, P | |
dc.contributor.author | Mok, T | |
dc.date.accessioned | 2016-04-18T08:48:11Z | en |
dc.date.available | 2016-04-18T08:48:11Z | en |
dc.date.issued | 2016-03-28 | en |
dc.identifier.citation | Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. 2016: J Clin Oncol | en |
dc.identifier.issn | 1527-7755 | en |
dc.identifier.pmid | 27022118 | en |
dc.identifier.doi | 10.1200/JCO.2015.63.5888 | en |
dc.identifier.uri | http://hdl.handle.net/10541/605645 | en |
dc.description.abstract | Intracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study in ALK-positive non-small-cell lung cancer. | |
dc.language | ENG | en |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncology | en |
dc.title | Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. | en |
dc.type | Article | en |
dc.contributor.department | Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia | en |
dc.identifier.journal | Journal of Clinical Oncology | en |
html.description.abstract | Intracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study in ALK-positive non-small-cell lung cancer. |